Taken together, these findings showed that CXCR4 plays a role in primary resistance to trastuzumab in HER2 + breast cancer, and combined targeting of CXCR4 sensitizes the tumor cells to trastuzumab. This evidence concerns the gene ERBB2 and neoplasm.